Sugi Predict

Sugi Predict / Compounds / SCHEMBL637753

SCHEMBL637753

SCHEMBL637753

CC(C)(C)OC(=O)NCCC(C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ DRD2 P14416 5/20 0.47
▸ IDO1 P14902 3/20 0.44
▸ LMNA P02545 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ P2RY2 P41231 1/20 0.40
▸ MALT1 Q9UDY8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4583816 0.88 MEN1 (0.54) GAAMEN1KMT2AIDO1CNR1
SCHEMBL29182091 0.87 GAA (0.50) GAAMEN1KMT2ADRD2IDO1
SCHEMBL29182067 0.87 MEN1 (0.50) GAAMEN1KMT2AIDO1POLB
SCHEMBL21804779 0.87 MEN1 (0.50) GAAMEN1KMT2ADRD2IDO1
SCHEMBL23564593 0.86 GAA (0.46) GAAMEN1KMT2ADRD2IDO1
SCHEMBL192206 0.86 GAA (0.46) GAAMEN1KMT2ADRD2IDO1
SCHEMBL192205 0.86 GAA (0.46) GAAMEN1KMT2ADRD2IDO1
SCHEMBL1456271 0.86 MEN1 (0.47) GAAMEN1KMT2ADRD2IDO1
SCHEMBL2799821 0.86 MAPT (0.47) GAAMEN1KMT2ADRD2IDO1
SCHEMBL29182092 0.86 GAA (0.49) GAAMEN1KMT2APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12146004-B2 Polymyxin compounds and uses thereof SPERO THERAPEUTICS, INC. (US) 2024-11-19 — — US disclosed
US-20230340026-A1 COMPOUNDS NEW PHARMA LICENCE HOLDINGS LTD (MT) 2023-10-26 — — US disclosed
US-20230340026-A1 COMPOUNDS NEW PHARMA LICENCE HOLDINGS LTD (MT) 2023-10-26 — — US disclosed
US-20230340026-A1 COMPOUNDS NEW PHARMA LICENCE HOLDINGS LTD (MT) 2023-10-26 — — US disclosed
US-20180030092-A1 COMPOUNDS SPERO THERAPEUTICS, INC. 2018-02-01 — — US disclosed
US-20180030092-A1 COMPOUNDS SPERO THERAPEUTICS, INC. 2018-02-01 — — US disclosed
US-20180030092-A1 COMPOUNDS SPERO THERAPEUTICS, INC. 2018-02-01 — — US disclosed
EP-3224273-A1 COMPOUNDS New Pharma Licence Holdings Limited (MT) 2017-10-04 — — EP disclosed
WO-2016083531-A1 COMPOUNDS NEW PHARMA LICENCE HOLDINGS LIMITED (MT) 2016-06-02 — — WO disclosed
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2016-06-02 — — US disclosed
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS XENOPORT, INC. 2009-09-17 — — US disclosed
US-7572830-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2009-08-11 — — US disclosed
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-04-24 — — US disclosed
US-7300956-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-11-27 — — US disclosed
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-03-08 — — US disclosed
US-7109239-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2006-09-19 — — US disclosed
EP-1684694-A2 AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2006-08-02 — — EP disclosed
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline ARRAY BIOPHARMA INC. 2005-06-16 — — US disclosed
WO-2005051304-A2 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2005-06-09 — — WO disclosed
US-20050107334-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, ABAT, SI GAA 148/4885MEN1 4486/4885KMT2A 2442/4885
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI GAA 148/4885MEN1 4486/4885KMT2A 2442/4885
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS APEH, ABAT, GABARAPL1 GAA 98/4885MEN1 4558/4885KMT2A 2415/4885
US-20230340026-A1 COMPOUNDS BCAT1, BCAT2, CCNT1 GAA 3480/4885MEN1 1609/4885KMT2A 3019/4885
US-20180030092-A1 COMPOUNDS BCAT1, BCAT2, IL4I1 GAA 3178/4885MEN1 1503/4885KMT2A 3824/4885
US-12146004-B2 Polymyxin compounds and uses thereof BCAT1, BCAT2, PNISR GAA 4383/4885MEN1 2808/4885KMT2A 2701/4885
US-20050107334-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI GAA 148/4885MEN1 4486/4885KMT2A 2442/4885
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 GAA 2160/4885MEN1 2997/4885KMT2A 2166/4885
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline MTOR, CDK2, CLK2 GAA 3630/4885MEN1 3226/4885KMT2A 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.